Camrelizumab plus chemotherapy combined with consolidative radiotherapy as first-line treatment for oligometastatic esophageal squamous cell carcinoma (ESCORT-1ST-RT): A single-arm, open-label, phase II trial

被引：0
|
作者：
Huang, W. [1 ]
Han, D. [1 ]
Li, B. [2 ]
Dong, J. [2 ]
机构：
[1] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Jinan, Peoples R China
[2] Shandong First Med Univ, Radiotherapy Dept, Affiliated Canc Hosp, Jinan, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.1518
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1452P
引用
收藏
页码：S902 / S902
页数：1
相关论文
共 50 条
  • [11] Neoadjuvant camrelizumab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, open-label study
    Wang, Jianping
    Zhang, Jian
    Gao, Jie
    Zhao, Mengmeng
    Ma, Zhenkai
    ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2024, 33 (06): : 573 - 581
  • [12] Brain radiotherapy combined with camrelizumab and platinum-based chemotherapy as first-line treatment for advanced NSCLC with brain metastases: A multicenter, open-label, single-arm, phase II study
    Fan, Y.
    Xu, Y.
    Huang, Z.
    Xu, Y.
    Sheng, L.
    Li, H.
    Lu, H.
    Chen, K.
    Yu, S.
    Gong, L.
    Han, N.
    Xu, X.
    Qin, J.
    Xie, F.
    Hong, W.
    Huang, D.
    Chen, J.
    ANNALS OF ONCOLOGY, 2023, 34
  • [13] Preoperative administration of camrelizumab combined with chemotherapy for borderline resectable esophageal squamous cell carcinoma (BRES-1): study protocol of a single-arm, open-label, phase II study
    Yang, Hang
    Guo, Yanan
    Zhao, Jia
    Zhang, Yan
    Jiao, Jia
    Mu, Teng
    Hou, Zhichao
    Huang, Qi
    Zhang, Guoqing
    Li, Xiangnan
    Li, Jindong
    JOURNAL OF THORACIC DISEASE, 2024, 16 (07) : 4702 - 4710
  • [14] Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma
    Zhang, Bo
    Qi, Ling
    Wang, Xi
    Xu, Jianping
    Liu, Yun
    Mu, Lan
    Wang, Xingyuan
    Bai, Lidan
    Huang, Jing
    CANCER COMMUNICATIONS, 2020, 40 (12) : 711 - 720
  • [15] Camrelizumab combined with paclitaxel and nedaplatin in the first-line treatment of locally advanced/advanced esophageal squamous cell carcinoma: A phase II, single-arm, exploratory research
    Wang, X.
    Ma, J.
    Zhang, J.
    Yang, Y.
    Zheng, D.
    Liang, H.
    Zhang, L.
    Xin, Y.
    Ling, X.
    Fang, C.
    Jiang, H.
    Zheng, W.
    ANNALS OF ONCOLOGY, 2021, 32 : S1400 - S1400
  • [16] CAMRELIZUMAB COMBINED WITH PACLITAXEL AND NEDAPLATIN IN THE FIRST-LINE TREATMENT OF LOCALLY ADVANCED/ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A PHASE II, SINGLE-ARM, EXPLORATORY RESEARCH
    Ma, Jianqun
    Zhang, Jinfeng
    Yang, Yingnan
    Zheng, Dayong
    Wang, Xiaoyuan
    Liang, Hao
    Zhang, Luquan
    Xin, Yanzhong
    Ling, Xiaodong
    Fang, Chengyuan
    Jiang, Hao
    Zheng, Wei
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A437 - A437
  • [17] Camrelizumab plus apatinib in patients with recurrent or metastatic nasopharyngeal carcinoma failing first-line therapy: An open-label, single-arm, phase II study
    Ding, X.
    Zhang, W.
    You, R.
    Zou, X.
    Wang, Z.
    Ouyang, Y-F.
    Liu, Y-L.
    Peng, L.
    You-Ping, L.
    Duan, C-Y.
    Yang, Q.
    Lin, C.
    Yulong, X.
    Chen, S-Y.
    Gu, C-M.
    Huang, P. Y.
    Hua, Y.
    Chen, M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S846 - S846
  • [18] Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial
    Meng, Xiangrui
    Wu, Tao
    Hong, Yonggui
    Fan, Qingxia
    Ren, Zhonghai
    Guo, Yanzhen
    Yang, Xiuli
    Shi, Pei
    Yang, Jiamei
    Yin, Xianzhe
    Luo, Zhiquan
    Xia, Jin
    Zhou, Yue
    Xu, Mengli
    Liu, Enjie
    Jiang, Guozhong
    Li, Shenglei
    Zhao, Feng
    Ma, Chi
    Ma, Chuanxiang
    Hou, Zhiguo
    Li, Jing
    Wang, Junsheng
    Wang, Feng
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2022, 7 (03): : 245 - 253
  • [19] Camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma (ESCC): A single-arm, phase II trial
    Gong, Lei
    Yang, Yueyang
    Zhang, Hongdian
    Qiao, Yufeng
    Wang, Haitong
    Ren, Peng
    Tang, Peng
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [20] Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma
    Liu, Jun
    Yang, Yang
    Liu, Zhichao
    Fu, Xiaolong
    Cai, Xiaoyue
    Li, Hongxuan
    Zhu, Li
    Shen, Yan
    Zhang, Hong
    Sun, Yifeng
    Chen, Hezhong
    Yu, Bentong
    Zhang, Renquan
    Shao, Jinchen
    Zhang, Ming
    Li, Zhigang
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (03)
12345